13F Holdings
中文EN

RCUS Arcus Biosciences, Inc.

Pharmaceutical Preparations · NYSE · SEC CIK 1724521 · Fiscal year ends 12/31

Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY-58.3%
TTM net income YoY-32.8%
TTM EPS YoY-6.4%
Revenue 3-yr CAGR-5.9%
Net income 3-yr CAGR—

Margins

Gross margin—
Operating margin-475.0%
Net margin-453.0%
FCF margin-466.0%
EBITDA margin-465.0%

Returns

ROE-114.1%
ROA-50.6%
ROIC (approx.)-124.0%
Asset turnover0.11x

Leverage & solvency

Liabilities / assets56.2%
Debt / equity0.28x
Current ratio3.34x
Interest coverage-43.18x

Cash quality & payout

Operating cash flow / net income1.03x
Accruals ratio1.3%
Payout ratio—
Capex / revenue1.0%

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item FY20252025-12-31FY20242024-12-31FY20232023-12-31FY20222022-12-31FY20212021-12-31
Income statement
Revenue$247.00M$258.00M$117.00M$112.00M$383.00M
R&D expense$523.00M$448.00M$340.00M$288.00M$257.00M
SG&A expense$110.00M$120.00M$117.00M$104.00M$72.00M
Operating income-$386.00M-$330.00M-$340.00M-$280.00M$54.00M
Interest expense$8.00M$4.00M$2.00M$2.00M—
Pretax income-$353.00M-$282.00M-$301.00M-$266.00M$55.00M
Income tax$0$1.00M$6.00M$1.00M$2.00M
Net income-$353.00M-$283.00M-$307.00M-$267.00M$53.00M
EBITDA-$376.00M-$320.00M-$332.00M-$274.00M$58.00M
EPS (basic)-3.29-3.14-4.15-3.710.76
EPS (diluted)-3.29-3.14-4.15-3.710.71
Weighted avg. shares (diluted)107.40M90.10M74.00M72.00M74.00M
Balance sheet
Cash & equivalents$222.00M$150.00M$127.00M$206.00M$148.00M
Short-term investments$759.00M$828.00M$632.00M$803.00M$351.00M
Current assets$1.01B$1.02B$831.00M$1.07B$1.26B
PP&E, net$40.00M$47.00M$51.00M$35.00M$32.00M
Total assets$1.14B$1.15B$1.09B$1.34B$1.59B
Current liabilities$231.00M$226.00M$184.00M$193.00M$166.00M
Long-term debt$99.00M$48.00M$0——
Total debt$99.00M$48.00M$0——
Total liabilities$508.00M$665.00M$633.00M$688.00M$750.45M
Shareholders' equity$631.00M$485.00M$462.00M$657.00M$842.00M
Net debt-$123.00M-$102.00M-$127.00M——
Shares outstanding125.30M92.20M75.50M72.90M70.80M
Cash flow statement
Operating cash flow-$482.00M-$170.00M-$306.00M$438.00M-$256.00M
Capital expenditure$2.00M$6.00M$24.00M$6.00M$26.00M
Free cash flow-$484.00M-$176.00M-$330.00M$432.00M-$282.00M
Investing cash flow$66.00M-$84.00M$194.00M-$413.00M-$4.00M
Financing cash flow$488.00M$277.00M$33.00M$33.00M$237.00M
Depreciation & amortization$10.00M$10.00M$8.00M$6.00M$4.00M
Stock-based compensation$60.00M$76.00M$73.00M$65.00M$55.00M

Free plan shows the latest 5 periods; Pro shows all 10 🔒

· This company does not report gross profit in XBRL.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.